UA55218A - Способ прогнозирования хронического гломерулонефрита у детей - Google Patents
Способ прогнозирования хронического гломерулонефрита у детей Download PDFInfo
- Publication number
- UA55218A UA55218A UA2002076065A UA200276065A UA55218A UA 55218 A UA55218 A UA 55218A UA 2002076065 A UA2002076065 A UA 2002076065A UA 200276065 A UA200276065 A UA 200276065A UA 55218 A UA55218 A UA 55218A
- Authority
- UA
- Ukraine
- Prior art keywords
- glomerulonephritis
- children
- remission
- chronic
- clinical
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 15
- 230000001684 chronic effect Effects 0.000 title abstract description 8
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 30
- 231100000749 chronicity Toxicity 0.000 claims description 12
- 210000002381 plasma Anatomy 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 2
- 238000012876 topography Methods 0.000 claims 1
- 101800004490 Endothelin-1 Proteins 0.000 abstract description 22
- 201000010099 disease Diseases 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 102100033902 Endothelin-1 Human genes 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 1
- 102400000686 Endothelin-1 Human genes 0.000 description 20
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 9
- 238000003745 diagnosis Methods 0.000 description 9
- 230000003907 kidney function Effects 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 230000001771 impaired effect Effects 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 206010018366 Glomerulonephritis acute Diseases 0.000 description 6
- 231100000851 acute glomerulonephritis Toxicity 0.000 description 6
- 206010044008 tonsillitis Diseases 0.000 description 6
- 238000009535 clinical urine test Methods 0.000 description 5
- 238000004393 prognosis Methods 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 206010065673 Nephritic syndrome Diseases 0.000 description 4
- 208000037849 arterial hypertension Diseases 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 208000006750 hematuria Diseases 0.000 description 4
- 208000017169 kidney disease Diseases 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000002485 urinary effect Effects 0.000 description 4
- 206010058314 Dysplasia Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 201000001474 proteinuria Diseases 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 206010009152 Chronic tonsillitis Diseases 0.000 description 2
- 206010011730 Cylindruria Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 206010020608 Hypercoagulation Diseases 0.000 description 2
- 208000008852 Hyperoxaluria Diseases 0.000 description 2
- 206010030302 Oliguria Diseases 0.000 description 2
- 206010033546 Pallor Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000002744 anti-aggregatory effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 210000000544 articulatio talocruralis Anatomy 0.000 description 2
- 230000035606 childbirth Effects 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 230000008576 chronic process Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 230000003027 hypercoagulation Effects 0.000 description 2
- 230000000544 hyperemic effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 150000003891 oxalate salts Chemical class 0.000 description 2
- 210000002741 palatine tonsil Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- UWGHBOXQOJIGDX-QESCWDNQSA-M potassium;n,n'-dibenzylethane-1,2-diamine;2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabic Chemical compound [K+].CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.C=1C=CC=CC=1CNCCNCC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 UWGHBOXQOJIGDX-QESCWDNQSA-M 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 150000007971 urates Chemical class 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 208000037157 Azotemia Diseases 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 208000019758 Hypergammaglobulinemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 206010025280 Lymphocytosis Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Natural products N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010061927 Pyelocaliectasis Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 208000012931 Urologic disease Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000003602 anti-herpes Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 229940097633 capoten Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 229940107200 chondroitin sulfates Drugs 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 229940088529 claritin Drugs 0.000 description 1
- 239000012568 clinical material Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- UOMKBIIXHQIERR-UHFFFAOYSA-N cridanimod Chemical compound C1=CC=C2N(CC(=O)O)C3=CC=CC=C3C(=O)C2=C1 UOMKBIIXHQIERR-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical group C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 210000004276 hyalin Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000005184 irreversible process Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000008775 paternal effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
- 208000008281 urolithiasis Diseases 0.000 description 1
- 229940108442 valtrex Drugs 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Calculators And Similar Devices (AREA)
Abstract
Предлагаемый способ прогнозирования хронического гломерулонефрита у детей заключается в том, что в плазме крови пациента определяют содержание эндотелина-1 в течение периода начальных клинических проявлений болезни, в течение периода ремиссии и через 3 и 6 месяцев после ремиссии, и сравнивают полученные данные с данными при нормальном состоянии пациента. Хронический гломерулонефрит прогнозируют в случае, если содержание эндотелина-1 в течение периода ремиссии и через 3 и 6 месяцев после ремиссии превышает нормальное содержание более чем на 2,723 ± 0,264 пмоль/л.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA2002076065A UA55218A (ru) | 2002-07-22 | 2002-07-22 | Способ прогнозирования хронического гломерулонефрита у детей |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA2002076065A UA55218A (ru) | 2002-07-22 | 2002-07-22 | Способ прогнозирования хронического гломерулонефрита у детей |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA55218A true UA55218A (ru) | 2003-03-17 |
Family
ID=74320132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2002076065A UA55218A (ru) | 2002-07-22 | 2002-07-22 | Способ прогнозирования хронического гломерулонефрита у детей |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA55218A (ru) |
-
2002
- 2002-07-22 UA UA2002076065A patent/UA55218A/ru unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Agarwal et al. | Prognostic factors in patients hospitalized with diabetic ketoacidosis | |
| Riva et al. | Faecal cytokine profiling as a marker of intestinal inflammation in acutely decompensated cirrhosis | |
| Chen et al. | The effect of serum neutrophil gelatinase-associated lipocalin on the discontinuation of continuous renal replacement therapy in critically ill patients with acute kidney injury | |
| CN111602057A (zh) | 使用降钙素原和中区肾上腺髓质素原的风险评估和患者管理的工作流程 | |
| Honsawek et al. | Elevation of serum galectin-3 and liver stiffness measured by transient elastography in biliary atresia | |
| Horvath et al. | Assessment of exocrine pancreatic function during endoscopy in children | |
| Battersby et al. | Differential diagnosis and treatment of acute diarrhoea in the dog and cat | |
| CN113056675A (zh) | 用于对具有感染性疾病症状的患者的需要住院的医学状况的风险进行预后的pro-ADM | |
| UA55218A (ru) | Способ прогнозирования хронического гломерулонефрита у детей | |
| Braun et al. | Barrier function of the gut and multiple organ dysfunction after cardiac surgery | |
| US20230074127A1 (en) | Test and in vitro diagnosis of irritable bowel syndrome | |
| Arisanti et al. | Calprotectin and intestinal fatty acid binding protein (I-FABP) level in preterm neonates with necrotizing enterocolitis | |
| Tasian et al. | Unilateral hypercalciuria: a stealth culprit in recurrent ipsilateral urolithiasis in children | |
| Khalifa et al. | Ascitic fluid lactoferrin as a diagnostic marker for spontaneous bacterial peritonitis | |
| RU2817667C1 (ru) | Способ оценки проницаемости эпителиального барьера кишечника у больных, получающих лечение гемодиализом | |
| Deniz et al. | Relationship of zonulin levels with thyroid function and metabolic parameters in Hashimoto's thyroiditis | |
| RU2800820C1 (ru) | Способ оценки комплаентности к аглютеновой диете у больных глютенчувствительной целиакией | |
| Jana et al. | Adhesive diseases in children. Prevention, diagnosis and treatment strategies | |
| UA70904A (en) | Method for predicting chronic glomerulonephritis imethod for predicting chronic glomerulonephritis in children n children | |
| Durga | Clinical profile and outcome of acute kidney injury in neonatal sepsis in a tertiary care centre | |
| RU2767892C1 (ru) | Способ определения тяжести течения внебольничной пневмонии у пациентов с хронической почечной недостаточностью | |
| Aburahma et al. | Changes of Serum Electrolytes and Serum Vitamin C Levels in a Sample of Iraqi patients Infected with Helicobacter pylori (H. pylori) | |
| RU2761732C1 (ru) | Способ дифференциальной диагностики уремического псевдоперитонита и перитонита у пациентов, получающих заместительную почечную терапию - программный гемодиализ | |
| KARAHAN et al. | Celiac Crisis: A Rare and Serious Condition Resulting in Death | |
| Vinel et al. | Biomarkers of necrotizing enterocolitis through the prism of etiopathogenesis |